142 related articles for article (PubMed ID: 36671475)
1. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
[TBL] [Abstract][Full Text] [Related]
2. Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development.
Chen Y; Jiang N; Chen M; Sui B; Liu X
Front Cell Dev Biol; 2022; 10():1064754. PubMed ID: 36467412
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
Huang X; Zhang G; Tang T; Liang T
Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
5. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
6. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
7.
Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
[TBL] [Abstract][Full Text] [Related]
8. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
Wang F
Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
[TBL] [Abstract][Full Text] [Related]
9. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
Front Immunol; 2021; 12():709986. PubMed ID: 34512630
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
You W; Ouyang J; Cai Z; Chen Y; Wu X
Front Immunol; 2022; 13():827506. PubMed ID: 35874675
[TBL] [Abstract][Full Text] [Related]
11. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
12. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
Front Genet; 2022; 13():853113. PubMed ID: 35734437
[No Abstract] [Full Text] [Related]
13. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
14. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
Hu J; Mo Z
Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
[TBL] [Abstract][Full Text] [Related]
15. Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines.
Chen Y; Zhang C; Li Y; Tan X; Li W; Tan S; Liu G
Sci Rep; 2024 Feb; 14(1):3219. PubMed ID: 38331967
[TBL] [Abstract][Full Text] [Related]
16. HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.
Chen Y; Yang J; Jin H; Wen W; Xu Y; Zhang X; Wang Y
PeerJ; 2023; 11():e16237. PubMed ID: 37842043
[TBL] [Abstract][Full Text] [Related]
17. Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets.
Shen Y; Liu J; Zhang L; Dong S; Zhang J; Liu Y; Zhou H; Dong W
Biomed Res Int; 2019; 2019():7376034. PubMed ID: 31485443
[TBL] [Abstract][Full Text] [Related]
18. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.
Zhang F; Liu Y; Yang Y; Yang K
BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731
[TBL] [Abstract][Full Text] [Related]
20. AVPR2 is a potential prognostic biomarker and correlated with immune infiltration in head and neck squamous cell carcinoma.
Mao L; Pan Z; Chen W; Hu W; Chen X; Dai H
BMC Med Genomics; 2023 Mar; 16(1):67. PubMed ID: 36998036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]